Linking Immune Exhaustion and Bone Health Markers to Frailty in HIV Patients

Overview

Frailty occurs earlier and more frequently in people with HIV despite antiretroviral therapy, driven by immune exhaustion and inflammation. Freeman et al identified immune checkpoint markers and osteoprotegerin as key factors associated with frailty, suggesting new therapeutic targets.

Background

Antiretroviral therapy (ART) has extended the lifespan of people living with HIV-1, but frailty remains a prevalent and early-onset syndrome in this population. Frailty is characterized by decreased physical performance and energy reserves, increasing vulnerability to adverse outcomes. Its diagnosis is complicated by overlapping inflammatory conditions and a lack of specific biological markers. Understanding immune and bone-related markers linked to frailty could guide targeted interventions.

Data Highlights

Key Findings

• Frailty in HIV patients is associated with elevated cytokines regulated by NF-κB, including IL-6, part of the senescence-associated secretory phenotype.
• No direct link was found between frailty and senescent T-cell markers p16INK4a or CD57 expression.
• Frailty correlates strongly with exhausted T-cell subpopulations expressing immune checkpoint markers PD-1 and TIGIT, especially in CX3CR1−CCR7− CD4 and CD8 T cells.
• Lower proportions of naive CD4 T cells and increased memory T cells are observed in frail individuals, reflecting immune aging and activation.
• Osteoprotegerin (OPG), a regulator of bone resorption and immune function, is elevated in frail HIV patients and linked to immune exhaustion markers, suggesting a bone-immune axis in frailty.
• Confounders such as depression, smoking, and statin use may influence biological aging and frailty but were not fully accounted for.

Clinical Implications

Assessment of immune exhaustion markers such as PD-1 and TIGIT alongside bone health markers like osteoprotegerin may improve frailty evaluation in HIV patients. Targeting dysfunctional T-cell subsets and modulating bone-immune interactions could offer novel therapeutic strategies to mitigate frailty. Multidisciplinary approaches are essential to address the complex interplay of immune aging, inflammation, and bone health in this population.

Conclusion

This study highlights immune exhaustion and bone-related pathways as critical contributors to frailty in ART-treated HIV patients, providing a foundation for targeted interventions to improve patient outcomes. Further research is needed to validate these findings and develop effective therapies.

References

1. Freeman et al. 2024 -- Immune and Bone Markers Associated with Frailty in HIV
2. Fried et al. -- Frailty Criteria and Assessment
3. Medawar 1971 -- Senescence and Immune Dysfunction